| NCT04243889 | Early Feasibility Study: Fetoscopic NEOX Cord 1K® Myelomeningocele (MMC) Repair | The University of Texas Health Science Center, Houston | | - Age 0 - 0 yrs
- Level C1-S5
AIS A, B, C, D- ≥ 0 hours
| Recruiting | | | Surgery | General health | | | Never | Never | 1 | |
| NCT04232657 | Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI | VA Office of Research and Development | | - Age 18 - 50 yrs
- Level C4-T10
AIS A, B- ≥ 3 years
| Active | 36 | PHASE2 | Drug | Bone health | | | 01 March 2021 | 18 January 2020 | 3 | |
| NCT04193709 | Recovery of Bladder and Sexual Function After Human Spinal Cord Injury | University of Louisville | | - Age 18 - 70 yrs
- Level C1-S5
AIS A, B, C, D- ≥ 1 months
- Participants that will receive epidural stimulation must:
- have a prior implantation of a Medtronic spinal cord epidural stimulation array
- use intermittent catheterization for bladder emptying.
- All participants must:
- have one of the following ASIA impairment scale (AIS):
- AIS A: complete; no feeling or movement below the injury
- AIS B: incomplete; have some feeling, but no movement, below the injury
- AIS C: incomplete; at least some feeling and mostly weak movement below the injury
- AIS D: incomplete; at least some feeling and, some weak but mostly stronger movement below the injury)
- have a neurogenic bladder and bowel dysfunction.
- be between the ages of 18 and 70 years old.
| Recruiting | 70 | NA | Technology | Bladder health/function | | | 04 January 2021 | 10 December 2019 | 1 | |
| NCT04171375 | Restorative Neuromodulation for Lower Extremity Functions | The Hong Kong Polytechnic University | | - Age 19 - 55 yrs
- Level C1-S5
AIS A, B, C, D- 1 years - 55 years
- have a spinal cord injury for at least 1 year.
- have paralysis in the legs and have at least half of key muscles below the neurological level of injury with a motor strength testing score less than 2/5.
- be able to participate in study exercises 1-2 hours per day and commit for 1 year training program.
- be between the ages of 19 and 55 years.
| Ended | 2 | NA | Technology | General health | | | 01 April 2019 | 20 November 2019 | 1 | |
| NCT04148573 | Clinical Trial to Evaluate Safety, Tolerability and Efficacy of NFX88 in SCI | Neurofix S.L. | | - Age 18 - 65 yrs
- Level C1-T12
AIS A, B, C, D- ≥ 0 hours
| Ended | 44 | PHASE2 | Drug | General health | | | 01 October 2019 | 01 November 2019 | 9 | |
| NCT04144972 | Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain | University of California, San Francisco | | - Age 22 - 80 yrs
- Level C1-S5
AIS A, B, C, D- ≥ 1 months
| Recruiting | 12 | NA | Technology | Pain | | | 24 October 2019 | 30 October 2019 | 1 | |
